Oncology | Phase II Developments | JAPAN

Eisai

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Eisai Announces Latest Data for LENVIMA® in Combination with Everolimus for Advanced Non-Clear Cell Renal Cell Carcinoma

Lead Product(s): Lenvatinib,Everolimus

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 15, 2020

Details:

The single-arm, multicenter, Phase 2 study of lenvatinib in combination with everolimus enrolled 31 patients with unresectable advanced or metastatic nccRCC.

Chugai Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Polatuzumab Vedotin Achieved Primary Endpoint in the Japanese study for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Lead Product(s): Polatuzumab Vedotin,Bendamustine,Rituximab

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 13, 2020

Details:

Polatuzumab vedotin in combination with bendamustine and rituximab achieved complete response rate in patients with relapsed or refractory diffuse large B-cell lymphoma.

Daiichi Sankyo Co Ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint

Lead Product(s): Trastuzumab Deruxtecan

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

Trial met primary endpoint of objective response rate and key secondary endpoint of overall survival in patients with previously treated HER2 positive metastatic gastric cancer.